Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24927595 | 0.88 | GAA (0.53) | GAADPP4ALDH1A1NPC1HDAC2 | |
| SCHEMBL8248045 | 0.83 | ALDH1A1 (0.38) | GAAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL9965485 | 0.82 | SMN1; SMN2 (0.39) | GAADPP4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL24927033 | 0.81 | DPP4 (0.44) | GAADPP4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL18743854 | 0.81 | POLB (0.37) | GAAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL8248084 | 0.79 | KDM4E (0.41) | GAADPP4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL8253762 | 0.78 | ALDH1A1 (0.38) | GAAALDH1A1SMN1; SMN2NPC1PAOX | |
| SCHEMBL24926540 | 0.78 | ANPEP (0.36) | GAAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL18743857 | 0.78 | ATM (0.47) | GAAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL13361637 | 0.75 | PAOX (0.38) | GAAKDM4CDPP4PAOXPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| EP-3150598-B1 | SUBSTITUTED TROPANE DERIVATIVES | TOA EIYO LTD (JP) | 2019-02-13 | — | — | EP | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-3150598-A1 | SUBSTITUTED TROPANE DERIVATIVES | TOA Eiyo Ltd. (JP) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | GAA 1390/4885KDM4C 602/4885DPP4 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.